Second-generation antipsychotics may exacerbate metabolic and inflammatory complications, with clozapine and olanzapine particularly implicated in insulin-resistance, poor glucose control, weight gain, type 2 diabetes mellitus (13), and increased C-reactive protein (CRP) and inflammatory cytokines (14, 15). Here, CRP is linked to type 2 diabetes mellitus.